bluebird bio to present LentiGlobin® BB305 Clinical Data and bb2121 Preclinical Data at Annual Meeting of the American Society of Hematology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Dow tick higher as investors weigh Mideast negotiations
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
bluebird bio (BLUE) Price Target Reduced to $149 at BofA/Merrill Lynch
November 6, 2015 7:34 AM ESTBofA/Merrill Lynch maintained a Buy rating on bluebird bio (NASDAQ: BLUE) but lowered its price target to $149.00 (from $241.00). Analyst Ying Huang reduced the addressable market for BB305 to 50% in severe thalassemia patients ineligible for stem cell transplant and lowered approval probability to 42%... More
Too Earlier to Write Off bluebird bio's (BLUE) LentiGlobin in Subset - Cowen
November 5, 2015 3:44 PM ESTCowen maintained an Outperform rating on bluebird bio (NASDAQ: BLUE). Shares declined after it announced data from its ongoing clinical studies of LentiGlobin will be highlighted in oral and poster presentations at the ASH meeting. In the view of analyst Eric Schmidt, it is far too early to conclude that LentiGlobin treatment will not lead to major benefits in beta0/beta0 patients.
"BLUE shares have come under pressure largely because beta0/beta0 subjects who make no endogenous beta chain Hb (the severest of beta-thal patients) have not achieved transfusion independence. In HGB-204,... More
bluebird bio (BLUE) Post-ASH Abstract Sell-Off an 'Overreaction', Oppenheimer Says
November 5, 2015 11:00 AM ESTOppenheimer analyst Wendy Lam weighed in on bluebird bio (NASDAQ: BLUE), saying the Post-ASH abstract sell-off is overdone.
Lam commented, "BLUE published six ASH abstracts this morning, three of which were focused on LentiGlobin in beta-thalassemia and sickle cell disease. Key updates disclosed in the abstracts include new data from additional patients treated in the Northstar and HBG-205... More
bluebird bio (BLUE) Plunges 14% in Early Trade Following ASH Update
November 5, 2015 8:20 AM ESTbluebird bio (NASDAQ: BLUE) is plunging 13.6% in pre-open trading following an update at ASH.
From the company's press release this morning:
bluebird bio, Inc. (Nasdaq: BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic diseases and T cell-based immunotherapies, announced that data from its ongoing clinical... More
